- Home
- NEN vs FTRE Comparison
NEN vs FTRE Comparison
Compare NEN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- FTRE
- Stock Information
- Founded
- NEN 1977
- FTRE 1996
- Country
- NEN United States
- FTRE United States
- Employees
- NEN N/A
- FTRE N/A
- Industry
- NEN Building operators
- FTRE Medical Specialities
- Sector
- NEN Real Estate
- FTRE Health Care
- Exchange
- NEN Nasdaq
- FTRE Nasdaq
- Market Cap
- NEN 277.7M
- FTRE 469.0M
- IPO Year
- NEN N/A
- FTRE N/A
- Fundamental
- Price
- NEN $77.25
- FTRE $5.95
- Analyst Decision
- NEN
- FTRE Hold
- Analyst Count
- NEN 0
- FTRE 11
- Target Price
- NEN N/A
- FTRE $18.00
- AVG Volume (30 Days)
- NEN 1.0K
- FTRE 2.3M
- Earning Date
- NEN 01-01-0001
- FTRE 05-12-2025
- Dividend Yield
- NEN 6.21%
- FTRE N/A
- EPS Growth
- NEN 87.60
- FTRE N/A
- EPS
- NEN 4.46
- FTRE N/A
- Revenue
- NEN $81,814,652.00
- FTRE $2,696,400,000.00
- Revenue This Year
- NEN N/A
- FTRE N/A
- Revenue Next Year
- NEN N/A
- FTRE $3.32
- P/E Ratio
- NEN $17.32
- FTRE N/A
- Revenue Growth
- NEN 8.57
- FTRE N/A
- 52 Week Low
- NEN $67.50
- FTRE $4.77
- 52 Week High
- NEN $84.00
- FTRE $37.24
- Technical
- Relative Strength Index (RSI)
- NEN 43.89
- FTRE 43.28
- Support Level
- NEN $77.00
- FTRE $5.40
- Resistance Level
- NEN $78.75
- FTRE $6.38
- Average True Range (ATR)
- NEN 0.45
- FTRE 0.45
- MACD
- NEN 0.05
- FTRE 0.21
- Stochastic Oscillator
- NEN 31.17
- FTRE 72.52
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.